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Abstract: Streptococcus pneumoniae infections lead to high morbidity and mortality rates worldwide.
Pneumococcal polysaccharide conjugate vaccines significantly reduce the burden of disease but have
a limited range of protection, which encourages the development of a broadly protective protein-based
alternative. We and others have shown that immunization with pneumococcal lipoproteins that lack
the lipid anchor protects against colonization. Since immunity against S. pneumoniae is mediated
through Toll-like receptor 2 signaling induced by lipidated proteins, we investigated the effects of
a lipid modification on the induced immune responses in either intranasally or subcutaneously
vaccinated mice. Here, we demonstrate that lipidation of recombinant lipoproteins DacB and PnrA
strongly improves their immunogenicity. Mice immunized with lipidated proteins showed enhanced
antibody concentrations and different induction kinetics. The induced humoral immune response
was modulated by lipidation, indicated by increased IgG2/IgG1 subclass ratios related to Th1-type
immunity. In a mouse model of colonization, immunization with lipidated antigens led to a moderate
but consistent reduction of pneumococcal colonization as compared to the non-lipidated proteins,
indicating that protein lipidation can improve the protective capacity of the coupled antigen. Thus,
protein lipidation represents a promising approach for the development of a serotype-independent
pneumococcal vaccine.
Keywords: Streptococcus pneumoniae; lipoproteins; lipidation; pneumococcal colonization; vaccine;
protection; immune response
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1. Introduction
Despite the implementation of pneumococcal polysaccharide conjugate vaccines (PCV),
Streptococcus pneumoniae (pneumococcus) is still a major cause of morbidity and mortality worldwide,
especially in young children, the elderly, and immune-compromised individuals [1,2]. The major
disadvantages of PCVs include the high manufacturing costs and limited serotype coverage, which
facilitates the replacement of vaccine serotypes by non-vaccine serotypes, hence requiring alternative
immunization strategies in the near future [3,4].
Because of these shortcomings, efforts have been made to develop novel vaccines based on
broadly representative, serotype-independent, highly conserved pneumococcal protein antigens.
Pneumococcal lipoproteins might be promising candidates for a future protein-based vaccine as they
represent the largest group of surface-exposed and conserved proteins of S. pneumoniae and contribute
to pneumococcal pathogenesis [5–7]. Indeed, various pneumococcal lipoproteins have been shown to
protect against pneumococcal infection in in vivo models [6,8,9].
Importantly, recognition of S. pneumoniae by the host immune system is characterized by
inflammation initiated through interactions between bacterial ligands and host cell surface receptors.
Among these, Toll-like receptors such as TLR2 play a fundamental role [10]. TLR2 has been shown
to be essential for clearance of S. pneumoniae in mouse colonization, meningitis, and otitis media
models [11–15]. Moreover, the generation of adaptive humoral and cellular immune responses to
S. pneumoniae is driven by TLR2 signaling, which has been shown to be involved in shaping immune
responses related to Th1-type immunity [15–17].
Thus, pneumococcal ligands stimulating TLR2 are important for the establishment of a potent
immune response. One of those ligands is the lipid moiety at the N-terminus of mature lipoproteins,
which enables embedding of these proteins into the cytoplasmic membrane [18]. In previous studies,
the immune-stimulating capacity of lipoproteins has been demonstrated and was shown to provide
protection against pneumococcal colonization. Vaccination of mice with lipidated proteins MalX
and GshT reduced the bacterial load in nasal washes compared to non-lipidated proteins, an effect
that was abrogated in TLR2-deficient mice [19]. In addition, lipidation and surface-localization of
lipoproteins were shown to be critical for the immunogenicity and protective capacity of pneumococcal
whole cell vaccines [20]. Importantly, protection against colonization was associated with increased
Interleukin (IL) 17A responses that were dependent on lipoprotein-driven activation of TLR2 [19,20].
In addition to IL-17A responses, antibody-mediated mechanisms have been shown to be crucial for
containment of pneumococcal colonization and subsequent lung infection [21–23]. With regard to
lipidated pneumococcal antigens, however, no detailed analyses of the humoral immune response
have been performed so far. Furthermore, it remains to be elucidated to what extent these responses
have an impact on the protection against pneumococcal colonization.
In the present study, we provide a detailed analysis of the lipidation-associated effects of
pneumococcal lipoproteins on the mouse immune response and the protective capacity of these lipidated
antigens. Two lipoproteins have been selected, l,d-carboxypeptidase DacB and the nucleoside-binding
protein PnrA, which have previously been shown to be involved in pneumococcal virulence and to
protect against pneumococcal colonization when used in the non-lipidated form [5,7,9]. Lipidated
DacB or PnrA were used in either intranasal or subcutaneous vaccinations to elucidate the impact
of the immunization route on the induced humoral immune response and protection. In addition,
the impact of adjuvantation was addressed in this study to evaluate whether the use of an adjuvant
has a beneficial effect on the immune response and protectivity of the model antigens used in this study.
We determined that antigen lipidation strongly influences the antibody induction kinetics and
leads to increased mucosal and systemic antibody levels. Moreover, lipidation modulates the induced
humoral immune response indicated by an increased IgG2/IgG1 subclass ratio related to Th1-type
immunity. However, local and systemic cytokine responses and thus cellular immune responses are
not strongly affected by protein lipidation. Following intranasal pneumococcal challenge, lipidation
mildly improves the protective capacity of the antigens against colonization. We show that, in addition
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to IL-17A, protection correlated with the elevated antibody levels induced by protein lipidation.
Therefore, lipidation of antigens is a promising strategy for the development of a serotype-independent
pneumococcal vaccine that would reduce pneumococcal carriage.
2. Materials and Methods
2.1. Cloning and Purification of Recombinant Lipidated and Non-Lipidated Proteins
For the generation of heterologous expression constructs of lipidated proteins, the vector
pETLip3 (kindly provided by Intervet MSD, Boxmeer, The Netherlands) was used, which contains
the signal sequence of the outer surface protein A (ospA) from Borrelia burgdorferi (Figures S1 and S2).
The corresponding genes for dacB (sp_0629 in TIGR4; nt 61–715, aa 21–238) and pnrA (sp_0845 in TIGR4;
nt 67–1050, aa 23–350) were amplified by polymerase chain reaction (PCR) without the signal sequences
from genomic DNA of the pneumococcal strain TIGR4 using specific oligonucleotide pairs listed
in Table 1.
Table 1. Primer list.
Primer Name/Restriction
Enzyme Purpose Sequence (5
′-3′) *
DacB_pETLip_forw
NdeI
Heterologous lipidation and
expression of DacB (SP_0629)
5′-GCGCCATATGCAAGAAAAAACAAAAAATGAAGATGGAGAAACTAAGAC-3′
DacB_pETLip_rev
BamHI 5
′-GCGGATCCTTAATGATGATGATGATGATGATCGACGTAGTCTCCGCC-3′
PnrA_pETLip_forw
NdeI
Heterologous lipidation and
expression of PnrA (SP_0845)
5′-GCGCCATATGGGTAACCGCTCTTCTCGTA-3′
PnrA_pETLip_rev
BamHI 5
′-GCGCGGATCCTTAATGATGATGATGATGATGTTTTTCAGGAACTTTTACGC-3′
* Restriction sites used for cloning are underlined. His6-tag in reverse primer is in italics.
The PCR products were inserted into the pETLip3 vector using the specific restriction sites
NdeI/BamHI incorporated in the forward and reverse primers, respectively. For purification of lipidated
proteins, reverse primers contained a sequence encoding for a C-terminal His6-tag. The constructs
for the recombinant expression of non-lipidated, His6-tagged DacB and PnrA were previously
described [5,9]. Recombinant plasmids were transformed into E. coli ClearColi® (Lucigen®, Middleton,
WI, USA), which were cultured in LBmodi medium (1% Bacto-Trypton, 0.5% yeast extract, 1% NaCl,
pH 7.5). Expression of His6-tagged proteins was induced with 1 mM IPTG. After lysis of E. coli
ClearColi® by sonication, lysates were either incubated with 20 mM zwitterionic detergent CHAPS
[3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate, Carl Roth, Karlsruhe, Germany] for
solubilization of lipidated proteins or directly centrifuged followed by affinity chromatography of
supernatants using HisTrap™ Ni-NTA columns in the “ÄKTA purifier liquid chromatography system”
(GE Healthcare GmbH, Freiburg im Breisgau, Germany). Purified proteins were dialyzed against
phosphate-buffered saline (PBS). Following SDS-PAGE, purity of the proteins was analyzed using silver
staining and immunoblotting. Immunoblots were performed with antigen-specific mouse antisera
(α-DacB, α-PnrA) and IRDye® 800CW goat anti-mouse IgG followed by detection using the Odyssey®
CLx Imaging System (LI-COR®, Bad Homburg, Germany).
2.2. Top-Down Analysis of Recombinant Proteins with LC–MS
Recombinant lipidated proteins were verified by liquid chromatography–mass spectrometry
(LC–MS). In a top-down analysis, protein samples were directly loaded onto the online desalting system
AdvanceBio Desalting-RP (Agilent, Santa Clara, CA, USA). The LC–MS system consisted of an HPLC
1100 (Agilent, Santa Clara, CA, USA) coupled to an electrospray ionization (ESI) mass spectrometer,
Q-Tof Ultima (Waters, Milford, MA, USA). The proteins were injected into the high-performance liquid
chromatography (HPLC) with aqueous 0.1% formic acid. Separation and elution of the lipidated proteins
were enabled by gradually increasing the hydrophobicity with 0.1% formic acid in acetonitrile. The mass
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spectra were externally calibrated with bovine ubiquitin (Sigma-Aldrich, Munich, Germany). Molecular
weights (MWs) of proteins were determined using ESIprot online for MS spectra deconvolution [24].
2.3. Surface Localization of Heterologously Expressed Proteins on E. coli ClearColi
To detect the heterologously expressed lipidated proteins on the surface of E. coli ClearColi®,
bacteria were sedimented and resuspended in PBS. Bacteria (2 × 108) were incubated with
antigen-specific mouse antisera (α-DacB, α-PnrA) for 45 min at 4 ◦C. After washing, bacteria were
incubated for 45 min at 4 ◦C with Alexa Fluor 488-coupled goat anti-mouse IgG. Bacteria were fixed
with 1% paraformaldehyde overnight at 4 ◦C. Flow cytometry was conducted with FACSCalibur™
(BD Biosciences, Heidelberg, Germany). The data were acquired by CellQuestPro Software 6.0
(BD Biosciences, Heidelberg, Germany) and analyzed with Flowing Software 2.5.1 (Perttu Terho, Cell
Imaging Core, Turku Centre for Biotechnology, Turku, Finland).
2.4. Mouse Model for Immunization and Pneumococcal Colonization
Animal experiments were conducted according to the Dutch law and with the approval
of the Radboud University Medical Center Committee for Animal Ethics (Ethic approval code
AVD103002017904). Six- to eight-week-old female inbred C57BL/6 mice (Charles River Laboratories,
Sulzfeld, Germany) were immunized intranasally (9 groups, n = 8) or subcutaneously (9 groups, n = 8)
three times in a two-week interval on days 0, 14, and 28. Vaccine formulations contained 5 µg lipidated
DacB (Lip-DacB), non-lipidated DacB (DacB), lipidated PnrA (Lip-PnrA), or non-lipidated PnrA
(PnrA) in a total volume of 10 µL or 50 µL for intranasal or subcutaneous immunizations, respectively.
While half of the groups per immunization route received vaccine formulations without adjuvant, in four
of the groups, adjuvant was added. Either 4 µg Cholera toxin subunit B (CTB, Sigma-Aldrich Chemie
GmbH, Taufkirchen, Germany) or 25 µL Imject™ Alum (ThermoFisher Scientific, Bonn, Germany)
was used for intranasal or subcutaneous vaccinations, respectively. One group per immunization
route (n = 8/group) received PBS as negative control. Tail vein blood samples were taken before each
immunization step on days-3, 11, and 25 (n = 4/group), and two weeks after the last immunization on
day 42 (n = 8/group) for antibody measurements. On day 49, three weeks after the final immunization,
mice were intranasally infected under inhalation anesthesia with 106 colony forming units (CFU)
of S. pneumoniae PBCN0231 (serotype 4) in 5 µL. On day 52, three days post-infection, mice were
euthanized, and blood, nasal tissue (n = 8/group), and spleens (n = 4/group) were harvested. The nasal
tissue was transferred in 1 mL PBS and homogenized using the disperser T 10 basic ULTRA-TURRAX®
in combination with the S 10 N–5 G Dispersing tool (IKA®-Werke GmbH & CO. KG, Staufen im
Breisgau, Germany). Nasal tissue homogenates were 10-fold serially diluted in PBS and plated on
blood agar plates to determine the bacterial recovery (CFU/mL nasal tissue homogenate). Remaining
nasal tissue homogenates were snap frozen in liquid nitrogen and stored at −80 ◦C until measurement
of local cytokine levels. Isolated spleens were directly transferred to culture medium (RPMI 1640
Glutamax + 10% FCS + 1% Pen/Strep) and kept on ice until further processing for in vitro stimulation.
2.5. In Vitro Cell Stimulations
HEK-Blue-hTLR2-TLR1, HEK-Blue-hTLR2-TLR6, and HEK-Blue-hTLR2-KO-TLR1/6 cells carrying
a SEAP reporter construct (InvivoGen, Toulouse, France) were grown in Gibco™ DMEM Glutamax
(Fisher Scientific, Landsmeer, The Netherlands) supplemented with 10% FCS, 2 mM L-glutamine,
100µg/mL Normocin in the presence of HEK-BLUE selective antibiotic according to the manufacturer’s
recommendations. When the cells reached 50–80% confluency, they were detached using 0.05%
Trypsin-EDTA (Lonza, Basel, Switzerland), washed once with PBS, resuspended in HEK-Blue
detection medium (InvivoGen, Toulouse, France), and used directly. For the assay, 5 × 105 cells were
stimulated with serial dilutions of purified DacB, Lip-DacB, PnrA, and Lip-PnrA (1 µg/mL–1 ng/mL)
in a final volume of 200 µL. Pam3CSK4 (EMC Microcollections, Tuebingen, Germany) and Pam2CSK4
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(InvivoGen) were included as positive controls for HEK-Blue-hTLR2-TLR1 and HEK-Blue-hTLR2-TLR6
cells, respectively. After 15 h of stimulation at 37 ◦C, 5% CO2, the OD at 620 nm was measured.
For in vitro splenocyte stimulations, single cell suspensions of spleens (n = 4/group) were prepared
in culture medium using a Falcon® 70 µm cell strainer (Fisher Scientific, Schwerte, Germany) followed
by incubation with red blood cell lysis buffer (Invitrogen, Karlsruhe, Germany) for 5 min. Splenocytes
(5 × 105 in 100 µL) were stimulated for 72 h at 37 ◦C and 5% CO2 with an equal volume of Lip-DacB
or Lip-PnrA (1 µg/mL), matching the immunization background. Lipidated proteins were used
for stimulation as these are the variants that are encountered during a natural infection. Cells
of PBS-treated animals were stimulated either with lipidated DacB or PnrA as a negative control.
Supernatants of stimulated splenocytes were collected and stored at −20 ◦C until measurement of
systemic cytokine levels.
2.6. Measurement of Cytokine Levels
Cytokine production in undiluted mouse nasal tissue homogenates (n = 8/group) or supernatants of
stimulated splenocytes (n = 4/group) were determined with LEGENDplex™ Mouse Th Cytokine Panel
(13-plex, BioLegend, London, UK). Except for reducing the used volumes described in the manual by
half, the assay was performed according to manufacturer’s instructions. Flow cytometry was conducted
with a BD LSR II (BD Biosciences, Heidelberg, Germany). The data were acquired by BD FACSDiva™
(BD Biosciences) and analyzed with LEGENDplex™ Data Analysis Software (BioLegend, London, UK).
2.7. Detection of Antibody Responses by Enzyme-Linked Immunosorbent Assay (ELISA)
Non-lipidated proteins were immobilized in equimolar amounts (3 pmol) on Maxisorp plates
(Laborhaus Scheller, Euerbach, Germany) overnight at 4 ◦C. For standard curves, wells were plated
with increasing concentrations of mouse IgA, IgG, IgG1, IgG2b, IgG2c, or IgG3 isotype control. Free
binding sites were blocked with 1% BSA. Plates were incubated for 1 h at 37 ◦C with 50 µL diluted
nasal tissue or serum sample followed by incubation for 1 h with 50 µL diluted secondary antibody.
Secondary antibodies used were peroxidase-coupled goat anti-mouse IgA, IgG, IgG2b, IgG2c, and IgG3
or rabbit anti-mouse IgG1. Antibody binding was detected with o-phenylenediamine dihydrochloride
(0.7 mg/mL in water) supplemented with 0.03% hydrogen peroxide. The color reaction was stopped by
2 M sulphuric acid followed by measurement of the absorbance at 492 nm with the FLUOstar Omega
microplate reader (BMG Labtech, Ortenberg, Germany).
2.8. Statistical Analyses
All statistical analyses were performed using GraphPad Prism version 5.0 (GraphPad Software,
San Diego, CA, USA). One-way ANOVA Kruskal–Wallis test with Dunn’s post-test or one-way ANOVA
with Bonferroni’s post-test were used to compare multiple groups. The Mann–Whitney U-test on
original data or one-sided t-test on log-transformed data was used to compare two groups. Spearman
correlation coefficients were calculated with control animals excluded to avoid bias of the strength
of correlation.
Multivariate redundancy analysis (RDA) was done using Canoco 5.11 with default settings of
the analysis type ‘Constrained’ [25]. RDA calculates p-values by randomly permuting the sample
status and thereafter counts the number of times a permuted set of samples has a better separation
compared to the non-permuted RDA model. Differences with a p-value < 0.05 were considered
statistically significant.
3. Results
3.1. Production of Recombinant Lipidated Proteins
Recombinant lipidated proteins Lip-DacB and Lip-PnrA were produced in E. coli ClearColi®
by the insertion of encoding genes for dacB and pnrA in the expression vector pETLip3. The genes
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were cloned downstream of the plasmid-encoded signal sequence of the gene coding for the outer
surface protein A (ospA) from Gram-negative Borrelia burgdorferi that enabled N-terminal lipidation
of proteins [26]. Heterologously expressed lipidated proteins were solubilized by treatment with
the zwitterionic detergent CHAPS and purified using affinity chromatography based on a C-terminal
His6-tag. Expression and purification of non-lipidated proteins were performed as described
previously [5,9]. Purity of recombinant proteins was verified by SDS-PAGE (Figure 1a). Strikingly,
in addition to the protein bands corresponding to the molecular weights (MWs) of the lipidated
proteins, SDS-PAGE revealed protein species with double MWs. Immunoblots with antigen-specific
antibodies confirmed that the lipidated proteins form dimers, possibly due to interactions of the lipid
moieties via van der Waals forces (Figure 1b).Vaccines 2020, 8, x  7 of 21 
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lipoprotein-specific antibodies (b). Total ion current chromatograms from HPLC of lipidated and non-
lipidated DacB (c) and PnrA (d). Separation and elution of the lipidated proteins was enabled by 
gradually increasing the hydrophobicity with 0.1% formic acid in acetonitrile. The peaks at retention 
time (RT) 3.4 min and RT 4.0 min reflect non-lipidated and lipidated proteins, respectively. The peak 
at RT 4.6/4.7 min represents phospholipids from the cell membrane. HEK-Blue-hTLR2-TLR1 (e) and 
HEK-Blue-hTLR2-TLR6 (f) cells were stimulated with increasing doses of Pam2CSK4, Pam3CSK4, 
lipidated, and non-lipidated proteins DacB or PnrA. Following stimulation in HEK-Blue detection 
medium over 15 h, the OD at 620 nm was measured. Mean results of three independent experiments 
are shown with error bars corresponding to SD. Equally stimulated HEK-Blue-hTLR2-KO-TLR1/6 
cells showed signals corresponding to the negative controls (Figure S4). 
3.2. Chemical Characterization and TLR2 Targeting of Recombinant Lipidated Proteins 
Figure 1. Characterization of lipidated and non-lipidated DacB and PnrA. Purified recombinant lipidated
and non-lipidated DacB and PnrA (each 1 µg) were separated by SDS-PAGE (12%) and detected either
by silver staining for validation of protein purification (a) or by immunoblots using lipoprotein-specific
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antibodies (b). Total ion current chromatograms from HPLC of lipidated and non-lipidated DacB (c)
and PnrA (d). Separation and elution of the lipidated proteins was enabled by gradually increasing
the hydrophobicity with 0.1% formic acid in acetonitrile. The peaks at retention time (RT) 3.4 min and RT
4.0 min reflect non-lipidated and lipidated proteins, respectively. The peak at RT 4.6/4.7 min represents
phospholipids from the cell membrane. HEK-Blue-hTLR2-TLR1 (e) and HEK-Blue-hTLR2-TLR6 (f)
cells were stimulated with increasing doses of Pam2CSK4, Pam3CSK4, lipidated, and non-lipidated
proteins DacB or PnrA. Following stimulation in HEK-Blue detection medium over 15 h, the OD
at 620 nm was measured. Mean results of three independent experiments are shown with error
bars corresponding to SD. Equally stimulated HEK-Blue-hTLR2-KO-TLR1/6 cells showed signals
corresponding to the negative controls (Figure S4).
The OspA of Borrelia burgdorferi is targeted to the outer surface by default [27]. Accordingly,
heterologous lipidation of DacB and PnrA in E. coli should similarly lead to their cell-surface exposure.
Therefore, E. coli ClearColi® strains expressing lipidated or non-lipidated DacB or PnrA were analyzed
by flow cytometry using antigen-specific antibodies (Figure S3). Targeting of lipidated proteins to
the surface was confirmed, thereby approving successful lipidation. However, fluorescence signals for
ClearColi® expressing Lip-DacB were higher compared to Lip-PnrA, suggesting that lipidation was
more efficient for Lip-DacB.
3.2. Chemical Characterization and TLR2 Targeting of Recombinant Lipidated Proteins
Gas chromatography–mass spectrometry (GC–MS) analysis of purified heterologously expressed
lipidated OspA revealed saturated fatty acids ranging from C14–C18 as well as C16 and C18 unsaturated
fatty acids, with palmitate (C16:0) being the major component [28]. Therefore, the main form
of N-terminal lipidation represents a S-[2,3-bis(palmitoyloxy)-(2R,S)-propyl]-N-palmitoylcysteine
modification, which is consistent with the model established by Hantke and Braun [29]. To further
confirm lipidation of DacB and PnrA, lipidated proteins were analyzed by LC–MS (Figure 1c,d;
Figures S5 and S6). The results of the analyses are summarized in Table 2.
Table 2. Theoretical and measured molecular weights of lipidated and non-lipidated proteins by LC–MS.
Protein Theoretical Mass * [Da] Retention Time [min] Measured Mass [Da] Mean Mass Difference ** [Da]
Non-lipidated proteins
DacB 26,614 3.4 26,615.1 ± 2 +1.1
PnrA 36,890 3.4
36,895 ± 1.2 (major) +5
36,937 ± 1 +47
Lipidated proteins
Lip-DacB 26,902
3.4 27,827.2 ± 0.5 +925.2 †
27,859.8 ± 0.7 +957.8 †
4.0 26,902.6 ± 0.2 +0.6 ‡
26,930.4 ± 0.2 +28.4 ‡, §
4.6 Phosphatidylethanolamines ¶
Lip-PnrA 37,177
3.4 38,106.5 ± 0.9 +929.5 †
4.0 37,209.1 ± 2.7 +32.1 ‡, §
4.7 Phosphatidylethanolamines ¶
* Theoretical masses for lipidated proteins assuming that three palmitate residues are attached to the N-terminal
cysteine of the protein sequences; ** Mean mass difference compared to the calculated theoretical mass for
tri-palmitoylated proteins; † Posttranslationally unmodified protein fraction carrying the OspA signal sequence;
‡ Lipidated protein fraction; § Mass differences of 28 or 32 Da explainable by replacement of one C16 by a C18 acyl
residue (∆mass = 28 Da) or by partial oxidations in the protein backbone at the cysteine and methionine positions
(∆mass = 32 Da); ¶ Phospholipids derived from the cell membrane.
According to the chromatograms from HPLC, preparations of non-lipidated proteins showed
one peak at a retention time (RT) of 3.4 min corresponding to non-lipidated DacB and PnrA
(Figure 1c,d). The elution profiles of lipidated DacB and PnrA were composed of three major
components. The lipidated protein fractions could be detected at RT 4.0 min with masses
corresponding to tri-palmitoylated proteins. The protein species at RT 3.4 min potentially represented
a post-translationally unmodified protein still carrying the OspA signal sequence (Figures S5 and S6).
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With respect to the yield, considerable amounts of lipidated protein could be achieved for Lip-DacB
(Figure 1c), which is indicated by a relatively high ratio of 0.67:1 of the lipidated (RT:4.0 min) to
non-lipidated protein fraction (RT:3.4 min). The amount of Lip-PnrA was significantly lower with
a ratio of 0.26:1 (Figure 1d).
Lipidated and non-lipidated proteins DacB and PnrA were used to stimulate HEK293 reporter
cells that are stably transfected with one of the heterodimers TLR2/1 or TLR2/6, respectively (Figure 1e,f;
Figure S4). In these assays, lipidated proteins activated both TLR2/1 and TLR2/6 in a dose-dependent
manner confirming engagement of TLR2 by the lipidated proteins. Activation by Lip-PnrA, however,
was consistently lower compared to Lip-DacB. Non-lipidated proteins elicited responses in HEK TLR2
cells comparable to the negative controls.
3.3. Protein Lipidation Enhances the Systemic Antibody Response in an Antigen-, Administration Route-,
and Adjuvant-Dependent Manner
The lipidated and non-lipidated proteins were used for intranasal or subcutaneous vaccinations of
C57BL/6 mice to study the impact of lipidation on the induced humoral immune responses. In addition,
mice were included that received an adjuvanted (CTB or Alum) formulation to study whether this,
together with lipidated antigens, leads to an enhanced humoral immune response or whether lipidation
itself is sufficient to potentiate antigen-specific antibody production (Figure 2).
Lipidation of DacB substantially impacted the magnitude of the induced systemic IgG responses
following intranasal immunization, irrespective of the use of CTB (Figure 2a). Non-lipidated DacB
elicited only marginal IgG responses when administered intranasally with or without adjuvant.
Intranasal vaccination with Lip-DacB increased the final IgG concentrations by five (without CTB) or
three orders (with CTB) of magnitude, whereas for PnrA, the effect of lipidation, also in the presence
of CTB, was minor. Notably, following subcutaneous immunization, protein lipidation resulted
in a statistically significant increase in antigen-specific IgG responses in all groups (Figure 2b).
IgG responses to both lipidated proteins were even higher than to alum-adjuvanted non-lipidated
proteins. IgG levels measured in pre-immune sera were negligible and close to the detection
limit (Figure S7). Interestingly, lipidation stimulated antibody production but did not create new
epitopes for antibody binding, as indicated by similar IgG levels detected in the ELISA when using
lipidated or non-lipidated protein for immobilization (Figure S8). Therefore, lipidation enhances
the immunogenicity of the coupled antigens but the lipid moiety itself is not immunogenic.
The effect of lipidation on the antibody kinetics over the course of each immunization was analyzed
for four mice per group (Figure 2c,d). Interestingly, the influence of lipidation on antibody kinetics was
primarily dependent on the immunization route. While IgG levels in the intranasal immunization were
still comparable between lipidated and non-lipidated proteins after priming, the following booster
immunizations significantly increased IgG levels in the presence of lipidation (Figure 2c). In contrast,
following subcutaneous immunization, lipidation had a major impact on IgG levels after the priming
immunization (Figure 2d). Strikingly, IgG levels induced by Alum-adjuvanted lipidated PnrA already
exceeded the final IgG concentrations induced by the Alum-adjuvanted non-lipidated PnrA after
the first immunization. In conclusion, lipidation had a substantial impact on the magnitude and
kinetics of the induced humoral immune response, which was dependent on the antigen, vaccination
route, as well as the adjuvant used.
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(n = 8/group) received three intranasal (a,c) or subcutaneous (b,d) vaccinations with 5 µg lipidated
or non-lipidated DacB or PnrA with or without additional adjuvant. Before each immunization and
two weeks after the third immunization, sera were collected and monitored for their antigen-specific
IgG concentrations using ELISA. Antigen-specific IgG levels (Log10 ng/mL) in post-immune sera of all
mice two weeks after the final immunization (a,b) and kinetics of IgG levels (Log10 ng/mL) following
each vaccination of four randomly selected mice per group (c,d) are shown. Box plots represent group
median (horizontal red line), first and third quartiles (box), and the range of data (whiskers). Symbols
represent individual mice. The dashed line indicates the lower limit of detection. Statistical significance
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3.4. Protein Lipidation Induces IgG Subclass Responses Related to Th1-Type Immunity
To elucidate the lipidation-induced T helper (Th) cell responses, IgG subclasses (IgG1, IgG2b,
IgG2c, IgG3) were measured in post-immune mouse sera (Figure 3a,b), while ratios of IgG subclass
concentrations of lipidated to non-lipidated (Lip:NonLip) DacB or PnrA were calculated to focus
on the lipidation-induced effects (Figure 3c,d).
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Overall, intranasal immunization with non-lipidated proteins and CTB induced a balanced
IgG2/IgG1 response with marginal IgG3 levels (Figure 3a). However, lipidation of DacB significantly
increased Lip:NonLip ratios of IgG1, IgG2b, IgG2c, and IgG3 by 20-, 1400-, 500-fold, and 16-fold,
respectively, indicating that lipidation not only enhanced antibody responses but also modulated
the induced type of IgG subclass response towards IgG2 (Figure 3c). Interestingly, lipidation of PnrA
resulted in an opposite effect following intranasal immunization with CTB. IgG subclass responses
were dominated by IgG2b (Figure 3a). However, compared to non-lipidated PnrA, significantly lower
levels of IgG1 and IgG2c were detected, with Lip:NonLip ratios of IgG1 and IgG2c reduced by 60- and
150-fold, respectively (Figure 3c).
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Subcutaneous immunization with non-lipidated proteins in combination with Alum induced
mainly antibodies of the IgG1 subclass, while levels of IgG2b, IgG2c, and IgG3 were significantly lower
(Figure 3b). However, when combined with Alum, lipidation of both proteins tested significantly
increased Lip:NonLip ratios of IgG2b, IgG2c, and IgG3 by 190-, 180-fold, and 3-fold, respectively, while
ratios of IgG1 remained unaltered (Figure 3d). Lipidated proteins without Alum induced a similar
pattern with increased levels of IgG2b and IgG2c and additionally an enhanced production of IgG1
compared to the non-lipidated proteins (Figure 3b,d). In addition, IgG3 concentrations for Lip-DacB
and Lip-PnrA were significantly elevated, reaching 250 and 46 times higher levels, respectively,
compared to the corresponding Alum-adjuvanted groups (Figure 3b).
In conclusion, dependent on the antigen, vaccination route, and adjuvant used, lipidation skewed
the IgG subclass responses towards IgG2 and partially IgG3, thus inducing IgG subclass responses
related to a Th1-type immunity.
3.5. Intranasal Immunization with Lipidated Proteins Enhances the Mucosal Antibody Response
in the Nasal Tissue
Since S. pneumoniae colonizes the mucosal surface of the upper respiratory tract, it is important
to determine antigen-specific antibodies available at this site of infection as they might play a role
in the containment of this pathogen [21,22]. Therefore, the nasal tissue of immunized mice that were
subsequently colonized with pneumococci for three days were assessed for mucosal antigen-specific
IgA and IgG levels (Figure 4).
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Figure 4. Impact of antigen lipidation on the local antibody response in the nasal tissue of mice.
Intranasally (a) or subcutaneously (b) immunized C57BL/6 mice (n = 8/group) were intranasally
infected with S. pneumoniae for three days followed by monitoring of nasal tissue homogenates for their
antigen-specific IgA and IgG concentrations (Log10 ng/mL) using ELISA. Box plots represent group
median (horizontal red line), first and third quartiles (box), and the range of data (whiskers). Symbols
represent individual mice. The dashed line indicates the lower limit of detection. Statistical significance
was determined using a Mann–Whitney U test. *, p < 0.05; ***, p < 0.001.
Although substantially lower IgG concentrations were measured in the nasal tissue, mucosal
levels showed a consistent pattern compared to the systemic levels. Significant mucosal IgA levels
could only be detected following intranasal immunization, whereas subcutaneous immunization did
not induce a detectable IgA response. Following intranasal immunization, lipidation significantly
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increased local IgA levels, with the exception of Lip-PnrA (Figure 4a). Interestingly, lipidation of
PnrA enhanced the IgA response when formulated with CTB, while local IgG levels were not affected.
These data show that protein lipidation is able to potentiate the systemic as well as the mucosal
humoral immune response.
3.6. Local and Systemic Cytokine Responses Are Not Significantly Driven by Protein Lipidation
Local and systemic cytokine profiles induced by immunization and subsequent pneumococcal
colonization were analyzed to elucidate whether immunization with lipidated proteins leads to
differences in cellular immunity upon encountering S. pneumoniae compared to non-lipidated proteins.
Therefore, cytokine levels were determined in the nasal tissue homogenates (of intranasally immunized
mice) and in supernatants of in vitro restimulated splenocytes (for both immunization routes) from
immunized and pneumococcal colonized mice, respectively.
Nasal tissue homogenates of intranasally immunized and pneumococcal colonized mice revealed
a tendency of any vaccine formulation to induce increased levels of pro-inflammatory cytokines
Interferon-γ (IFN-γ) and tumor necrosis factor alpha (TNF-α) compared to PBS-treated mice (Figure S9).
In the CTB-adjuvanted groups, significantly increased levels of local IL-17A could be detected
independent of lipidation.
Subsequently, nasal cytokine levels were used for supervised RDA to explore whether certain
cytokines correlated with either protein lipidation or adjuvantation (Figure 5a,b; Figure S10a,b).
Significant differences in cytokine profiles were observed between groups with and without CTB
adjuvant, with nasal IL-17A being the main driver for both proteins, i.e., DacB and PnrA (Figure S10a,b).
However, the RDA revealed no lipidation-associated cytokine profile when comparing the lipidated
and non-lipidated proteins (Figure 5a,b).
For the systemic cytokine profiles induced by immunization and subsequent pneumococcal
colonization, splenocytes were stimulated in vitro with either lipidated DacB or PnrA, matching
the vaccination background of the animal (Figure S11). Similar to the nasal cytokine profiles,
elevated systemic IL-17A levels were detected following intranasal immunization exclusively
in the CTB-adjuvanted groups independent of lipidation (Figure S11a). Following subcutaneous
immunization, Lip-PnrA in combination with Alum showed significantly increased levels of IFN-γ,
IL-6, IL-2, IL-17A, IL-22, and IL-13 compared to PBS-treated mice (Figure S11b).
As with nasal cytokine levels, systemic cytokine levels were used for RDA to explore whether
certain cytokines correlated with either protein lipidation or adjuvantation (Figure 5c–f, Figure S10c–f).
Thus, RDAs were performed per antigen using either the data from mice receiving lipidated antigens
compared to the non-lipidated variants, irrespective of the presence of an adjuvant (Figure 5c–f),
or comparing the data of adjuvanted and non-adjuvanted mice, independent of protein lipidation
(Figure S10c–f). RDAs showed no significant differences in cytokine profiles between mice intranasally
vaccinated with lipidated or non-lipidated proteins (Figure 5c,d), whereas co-administration with CTB
did (Figure S10c,d), which is in line with the nasal cytokine signature. For subcutaneous immunized
mice, RDA showed that both PnrA lipidation and co-administration with Alum significantly changed
the cytokine profile compared to no lipidation and no Alum, respectively, which was not the case for
DacB (Figure 5e,f; Figure S10e,f). This suggests that the vaccination background, including vaccination
route, adjuvant, and antigen, steers the splenocyte cytokine response. However, the data mainly
indicate that local and systemic cytokine responses are not strongly affected by protein lipidation.
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Figure 5. Impact of lipidation on the cytokine response in the nasal tissue or in in vitro restimulated
splenocytes of immunized and pneumococcal colonized mice. Nasal tissue of C57BL/6 mice (n = 8/group)
that were intranasally immunized with lipidated or non-lipidated DacB (a) or PnrA (b) followed by
an intranasal infection with S. pneumoniae three days prior to collection was analyzed. Cytokine
levels in tissue homogenate were used for RDA to determine local lipidation-specific cytokine
signatures for both proteins. Splenocytes were obtained from C57BL/6 mice (n = 4/group) that
were intranasally (c,d) or subcutaneously (e,f) immunized followed by the pneumococcal infection.
Cells were restimulated in vitro with lipidated proteins, matching the vaccination background, for 72 h.
The cytokine levels were assessed and used for RDA irrespective of additional adjuvantation to
evaluate systemic lipidation-specific cytokine signatures for DacB (c,e) and PnrA (d,f). Lipidation YES
refers to mice vaccinated with lipidated proteins; and Lipidation NO refers to mice vaccinated with
non-lipidated proteins. Arrows indicate individual cytokines, red triangles the sample group centroids,
and squares/circles represent individual mice. p-values are shown; p < 0.05 is considered significant.
3.7. Immunization with Lipidated Antigens Moderately Reduces the Nasal Bacterial Load Compared to
Non-Lipidated Variants
Next, we investigated whether the immunological differences induced by vaccination with either
lipidated or non-lipidated proteins have an impact on the level of protection against pneumococcal
colonization. Therefore, three weeks after the last immunization, mice were intranasally infected
with S. pneumoniae. Three days post-infection, mice were euthanized and viable pneumococci
were recovered from the nasal tissue (Figure 6a,b). Compared to PBS-treated mice, intranasal
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vaccination with CTB-adjuvanted proteins induced a significant reduction of the bacterial load
in the nasal cavity (Figure 6a). Vaccination with Lip-PnrA + CTB revealed the strongest effect, causing
a 350-fold reduction in nasal bacterial load. The impact of lipidation on protection was evaluated
independently of the antigen by comparing lipidated and non-lipidated proteins. Lipidated DacB
and PnrA significantly reduced the bacterial load by three and five times, respectively, compared to
the non-lipidated variant when no adjuvant was used (one-sided t-test; p[DacB:Lip-DacB] = 0.0306
and p[PnrA:Lip-PnrA] = 0.0167). Compared to PBS-treated mice, subcutaneously immunized mice
were not significantly protected against colonization with any of the vaccine formulations (Figure 6b).
However, protein lipidation tended to reduce the pneumococcal load in the nasopharynx, which
reached statistical significance for PnrA versus Lip-PnrA with a 3-fold and Alum-adjuvanted DacB
versus Lip-DacB with a 4.5-fold reduction (one-sided t-test; p = 0.0024 and p = 0.0153, respectively).Vaccines 2020, 8, x  15 of 21 
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correlates inversely with nasal antibody levels. The bacterial load (Log10 CFU/mL) in nasal tissue
of C57BL/6 mice three days post intranasal infection with 106 CFU S. pneumoniae was determined
following three intranasal (a) or subcutaneous (b) immunizations with 5 µg of lipidated or non-lipidated
DacB or PnrA with or without a ditional adjuva t. Symbo s r present individual mic , solid lines
the group median, a d the dashed line indicates the lower limit of detection. Data were statistically
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Increased mucosal antibody responses were detected in the nasal tissue that were significantly
impacted by lipidation (Figure 4). Following intranasal immunization, elevated levels of
nasopharyngeal IgA and IgG correlated inversely with the nasal bacterial load (Figure 6c,d), which was
not the case for the subcutaneous immunization (Figure S12). However, serum-derived IgG may have
had a significant impact on colonization, since it can reach the surface by paracellular diffusion through
the epithelium [30]. Based on correlations of systemic IgG subclass levels and nasal bacterial loads,
subclasses IgG2b and IgG2c in particular might have contributed to the reduction in the bacterial loads
(Figure S13). Of note, correlations of antibody levels reached higher significance for PnrA-immunized
compared to DacB-immunized mice. In addition, nasopharyngeal IL-17A levels that were increased
in the CTB-adjuvanted groups following intranasal immunization inversely correlated with protection
(Figure S14b,c).
Therefore, our data indicate an important role of a combination of IL-17A and antibodies
in protecting against pneumococcal colonization, the latter being significantly impacted by
protein lipidation.
4. Discussion
Pneumococcal lipoproteins are of major interest for the development of a broadly protective
protein-based vaccine. However, when produced recombinantly, these proteins lack their lipid moiety.
In the present study, we investigated whether the immunogenicity and the protection induced by
pneumococcal lipoproteins could be further improved by attaching a lipid anchor. To this end,
lipidated and non-lipidated DacB and PnrA were produced and evaluated in a mouse immunization
and colonization model.
Protein lipidation was characterized and validated by immunoblots, flow cytometry, a top-down
LC–MS analysis, and a TLR2 stimulation assay. In LC–MS, for lipidated DacB, a molecular weight
was identified that corresponds to an N-terminal tri-palmitoylation of the protein. However, slightly
different molecular weights were found for lipidated PnrA. Although palmitic acid is generally
the most predominant fatty acid, similar molecules within the cell envelope may serve as an acyl donor:
palmitoleic acid, cis-vaccenic acid, 9,10-methylene-hexadecanoic acid, and stearic acid, potentially
explaining the observed variability in lipidation [29]. In addition, the differences in the molecular
weights determined by mass spectrometry may be a result of partial oxidations in the protein
backbone [28,31]. In the TLR2 stimulation assay, both TLR2/1 and TLR2/6 heterodimers were
stimulated by either of the two lipidated proteins. Although triacylated proteins are recognized by
TLR2/1, there are studies indicating that activation through TLR2 can occur independent of TLR1 and
TLR6 [32]. Lipidation of DacB was more efficient than that of PnrA, although in both cases a substantial
amount of lipidated protein was produced. Interestingly, it is currently unknown how these differences
in lipidation efficiency relate to the wild-type lipidation of these proteins in S. pneumoniae. Moreover,
differences in lipidation mechanisms between Gram-positive and Gram-negative bacteria might also
have influenced the lipidation efficiency of our heterologous lipidation method [33]. Although highly
speculative, the observed differences in lipidation efficiency and/or moieties between DacB and PnrA
could possibly be a consequence of differences in amino acid features following the lipidation sequence.
Importantly, these differences between DacB and PnrA might have contributed to the protein-specific
effects of lipidation presented in this study.
A major finding of the present study is the improved antibody kinetics and levels following
immunization with lipidated proteins compared to non-lipidated proteins. This underpins that
lipidated DacB and PnrA possess self-adjuvanting activity. The most prominent differences in serum
IgG level between mice immunized with lipidated or non-lipidated proteins were observed after
the first intranasal booster vaccination or the priming subcutaneous vaccination. Possible explanations
for this difference between vaccination routes could be that (i) subcutaneous and intranasal vaccination
require a distinct antigen dose for the induction of comparable antibody levels, (ii) B cells recognizing
lipoproteins via TLR2 are activated and differentiate more efficiently following subcutaneous versus
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intranasal vaccination [34] and/or (iii) the sites of antigen deposition contain different densities and
types of antigen presenting cells, which vary in TLR2 expression level and, when activated, might
differentially stimulate B cell responses [35]. Interestingly, the enhanced antibody response was not
a consequence of newly created epitopes by protein lipidation. Of note, next to the administration route,
antibody induction was highly dependent on the adjuvant and antigen used, as has been described
before [36,37]. However, antibody kinetics were only measured for a small number of mice per group
(n = 4) and conclusions should therefore be interpreted with caution.
In addition to total IgG levels, protein lipidation influenced the antibody subclass distribution.
When comparing antibody subclasses induced by vaccination with lipidated proteins to non-lipidated
proteins, a major increase in IgG2b and IgG2c and a smaller increase in IgG3 were found, except
for intranasally administered PnrA. Therefore, our data show that protein lipidation increases
the IgG2/IgG1-ratio. This suggests that lipidation promotes skewing of the immune response towards
a Th1 phenotype, which has been associated with a protective anti-pneumococcal immune response [38,
39]. Moreover, murine IgG2 is found to be the most potent activator of effector responses, including
complement fixation, and might therefore be favorable for protection against S. pneumoniae [40,41].
The TLR2-mediated immune-modulating activity of protein lipidation demonstrated here is
in accordance with previously published studies. For instance, TLR2 signaling was shown to be
important for enabling a Th1-related IgG response to pneumococcal infection in mice [16]. Similarly,
lipidated Ag473 from serogroup B Neisseria meningitidis skewed T cell polarization towards a Th1
phenotype compared to non-lipidated Ag473 [42]. Besides TLR2, it is possible that Th1-biased immune
responses of lipidated DacB and/or PnrA are due to engagement of TLR4 receptors, which may lead to
profound differences in the initiation of downstream signaling pathways [43–45].
In contrast to the pronounced effect of lipidation on the humoral immune response, we found
hardly any effect on the cytokine responses, as almost none of the RDAs were statistically significant.
Co-administration of CTB in intranasal vaccine formulations increased the systemic and nasal IL-17A
levels and, consistent with previous studies, the nasal IL-17A concentrations correlated inversely with
the nasal pneumococcal load [15,46,47]. Interestingly, Th17 responses were found to be promoted
by TLR2 activation in dendritic cells as well as CD4+ T cells, and Th17-mediated protection of
a pneumococcal whole cell vaccine against carriage was dependent on TLR2 and surface-exposed
lipoproteins [20,48,49]. In addition, in vitro stimulation of whole blood from mice immunized with
lipidated proteins has been shown by others to induce elevated IL-17A levels compared to mice
immunized with non-lipidated proteins [19]. However, we could not demonstrate an effect of protein
lipidation on IL-17A levels. These discrepancies might be explained by differences in the experimental
setup, including cell type, stimuli, and adjuvant used. Moreover, the cytokine signatures measured
in this study should be interpreted with caution and subtle changes might have been missed, because
the data were generated using a small number of animals (n = 4 for spleen cell stimulations).
Furthermore, they are the result of a combined effect of the vaccine formulation used and the boosted
immune response as a consequence of the pneumococcal infection. This combination of immunization
and subsequent challenge also required the use of in vitro restimulated splenocytes as a measure of
systemic inflammatory reactions instead of commonly used whole blood [19] due to a limited amount
of blood samples.
Following pneumococcal challenge, solely mice that were intranasally vaccinated with
CTB-adjuvanted proteins were significantly protected against pneumococcal colonization compared
to PBS-treated mice, to a similar level as published previously for non-lipidated DacB and PnrA [9].
However, compared to the non-lipidated proteins, mice vaccinated with lipidated proteins showed
the tendency to reduce the nasal bacterial load following both vaccination routes. This effect is
comparable to that shown for lipidated versus non-lipidated MalX and GshT and suggests that
the altered immune response due to lipidation is able to contribute to improved protection against
colonization [19]. Despite the limited number of mice per group in the present study, we were able to
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reproduce the protective effect of the pneumococcal proteins DacB and PnrA, which was previously
shown with a heterologous pneumococcal strain, underscoring the validity of our data [9].
In intranasally vaccinated mice, the nasal IgA and IgG levels, which were enhanced by protein
lipidation, correlated inversely with the bacterial load. In addition, slightly reduced bacterial
loads following subcutaneous immunization with lipidated proteins might likewise be attributed to
a lipidation-induced increase in IgG levels. Although mucosal IgG levels of these subcutaneously
vaccinated mice did not correlate with the reduced bacterial loads, serum-derived IgG translocated
to the mucosal surface might have had an impact. It was found that especially the subclasses
IgG2b and IgG2c correlated inversely with the reduced bacterial loads following both vaccination
routes, indicating they may have contributed to the observed reduction. Of note, the unnaturally
high challenge dose (106 CFU) used for colonization might have partly hampered the measurement
of the vaccine-induced immunity, leading to an underestimation of the role of antibody-mediated
protection. Since antibodies have previously been shown to play a major role in protection, it is
tempting to speculate that vaccination with lipidated antigens would result in a significantly better
protection from invasive disease compared to vaccination with non-lipidated proteins [23,50].
5. Conclusions
In conclusion, we have shown that vaccination of mice with lipidated pneumococcal lipoproteins
results in improved quantity and quality of antibodies compared to vaccination with non-lipidated
proteins, but did not significantly influence the cellular immune response. Mice vaccinated with
lipidated proteins showed a mild but encouraging reduction in nasal bacterial load compared to mice
immunized with the non-lipidated variant. Therefore, lipidation of antigens represents a promising
approach for the development of novel pneumococcal vaccine formulations, which has to be validated
and extended in future studies using other pneumococcal antigens or combinations thereof.
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